Ads
related to: mdd symptoms
Search results
FDA expands age range for BrainsWay Deep TMS treatment By Investing.com
Investing.com· 47 minutes agoThis clearance is the 10th FDA approval for BrainsWay and marks the first time a TMS treatment has...
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression - BrainsWay (NASDAQ:BWAY)
Benzinga· 5 hours agoTranscranial Magnetic Stimulation system (Deep TMS™) allowing for the treatment of patients with major depressive disorder (MDD) ages 22 to 86, changing the previous upper ...
J&J’s seltorexant meets all endpoints in Phase III MDD trial
Clinical Trials Arena via Yahoo Finance· 4 days agoApproximately 60% of MDD patients on standard-of-care oral antidepressants experience residual...
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
Zacks via Yahoo Finance· 4 days agoData from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study...
J&J’s treatment for depression succeeds in late-stage study
KFGO· 5 days ago(Reuters) -Johnson & Johnson said on Wednesday its experimental drug, seltorexant, met all main and...
J&J's drug eases depression and insomnia symptoms in late-stage study
Reuters via AOL· 5 days ago(Reuters) -Johnson & Johnson's experimental drug helped reduce symptoms of depression as well as...
Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial
Benzinga via Yahoo Finance· 5 days agoSeltorexant is an investigational first-in-class selective antagonist of the human orexin-2 receptor...
J&J’s daily add-on pill improves depression and insomnia symptoms, acing phase 3
FierceBiotech· 5 days agoJohnson & Johnson’s oral add-on drug significantly improved depressive symptoms and sleep outcomes in a phase 3 trial for patients who previously did not benefit from antidepressants ...
AANA Issues Updated Practice Considerations for Ketamine Therapy for Psychiatric Disorders and...
The Southern Illinoisan· 6 days agoAnesthesiology (AANA) recently updated its practice considerations addressing ketamine therapy to cite the most current studies, as AANA continues to support a patient-centered, interdisciplinary ...
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major...
Digital Journal· 6 days agoThere were no statistically significant differences in change from baseline BAI total scores to week 6 between placebo and azetukalner groups. At baseline, the X-NOVA population, on average, ...
